Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

With Beyoncé’s Grammy win for Album of the Year on Sunday night, her husband, Jay-Z, who has writing credits on the popular project, is now the most awarded rapper in Grammy history.

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical giant’s CEO mentioned this in the Q4 earnings call ...

And just to be clear, Merck is a company I like, which, I believe, has amazing fundamentals. You don't need me to make the bull case for Merck: 9 of the last 10 articles on Seeking Alpha have a ...

Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...